Steenaard Rebecca V, Kerkhofs Thomas M A, Zijlstra Myrte, Mols Floortje, Kerstens Michiel N, Timmers Henry J L M, van Leeuwaarde Rachel S, Dreijerink Koen M A, Eekhoff Elisabeth M W, Nieveen van Dijkum Els J M, Corssmit Eleonora P M, Kapiteijn Ellen, Kremers Marjolein N T, Feelders Richard A, Haak Harm R
Department of Internal Medicine, Máxima MC, 5631 BM Eindhoven/Veldhoven, The Netherlands.
CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht University, 6229 HX Maastricht, The Netherlands.
Cancers (Basel). 2022 Mar 8;14(6):1366. doi: 10.3390/cancers14061366.
We aimed to develop a disease-specific adrenocortical carcinoma (ACC) health-related quality of life (HRQoL) questionnaire (ACC-QOL) and assess HRQoL in a population-based cohort of patients with ACC. Development was in line with European Organization for Research and Treatment of Cancer (EORTC) guidelines, though not an EORTC product. In phase I and II, we identified 90 potential HRQoL issues using literature and focus groups, which were reduced to 39 by healthcare professionals. Pilot testing resulted in 28 questions, to be used alongside the EORTC QLQ-C30. In Phase III, 100 patients with ACC were asked to complete the questionnaires twice in the PROFILES registry (3-month interval, respondents: first 67, second 51). Confirmatory factor analysis demonstrated the structural validity of 26 questions with their scale structure (mitotane side-effects, hypercortisolism/hydrocortisone effects, emotional effects). Internal consistency and reliability were good (Cronbach's alpha 0.897, Interclass correlation coefficient 0.860). Responsiveness analysis showed good discriminative ability (AUC 0.788). Patients diagnosed more than 5 years ago reported a good HRQoL compared with the Dutch reference population, but experienced residual fatigue and emotional problems. Patients who underwent recent treatment reported a lower HRQoL and problems in several domains. In conclusion, we developed an ACC-specific HRQoL questionnaire with good psychometric properties.
我们旨在开发一种针对肾上腺皮质癌(ACC)的特定疾病健康相关生活质量(HRQoL)问卷(ACC-QOL),并在基于人群的ACC患者队列中评估HRQoL。尽管不是欧洲癌症研究与治疗组织(EORTC)的产品,但开发过程符合EORTC指南。在第一阶段和第二阶段,我们通过文献检索和焦点小组确定了90个潜在的HRQoL问题,这些问题经医疗专业人员筛选后减少至39个。预试验产生了28个问题,将与EORTC QLQ-C30一起使用。在第三阶段,100名ACC患者被要求在PROFILES注册中心两次完成问卷(间隔3个月,第一次67名受访者,第二次51名)。验证性因素分析证明了26个问题及其量表结构(米托坦副作用、皮质醇增多症/氢化可的松效应、情绪效应)的结构效度。内部一致性和可靠性良好(Cronbach's alpha 0.897,组内相关系数0.860)。反应性分析显示出良好的鉴别能力(AUC 0.788)。与荷兰参考人群相比,5年前以上确诊的患者报告了良好的HRQoL,但仍有残余疲劳和情绪问题。近期接受治疗的患者报告了较低的HRQoL以及在几个领域存在问题。总之,我们开发了一种具有良好心理测量特性的ACC特异性HRQoL问卷。